Innovating Works

TAMIRNA

Desconocido
METABOLATE: METABOLic immuno-engineered biomATErials TAMIRNA GMBH participó en un HORIZON EUROPE: HORIZON-MSCA-2022-PF-01 Large bone defects display compromised healing associated with pronounced inflammation and constitute a major clinical problem. Recently, a...
2023-03-09 - 2025-07-20 | Financiado
FIDELIO: Training network for research into bone Fragility In Diabetes in Europe towards a personaLised med... TAMIRNA GMBH participó en un H2020: H2020-MSCA-ITN-2019 Diabetes mellitus has emerged as a novel risk factor for fragility fractures. While in type 1 diabetes the 3-fold overall relative risk for...
2019-09-04 - 2024-03-31 | Financiado
TransBioLine: Translational Safety Biomarker Pipeline TransBioLine Enabling development and implementation of n... TAMIRNA GMBH participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage Qualified biomarkers help to optimize drug development and patient safety, yet for the regulatory acceptance of safety biomarkers substantia...
2019-04-08 - 2025-01-31 | Financiado
OsteomiR: OsteomiR Test An In Vitro Test for the Diagnosis of Osteoporosis and associated Fracture Risk TAMIRNA GMBH tramitó un H2020: H2020-SMEInst-2014-2015 TAmiRNA aims to commercialize an in-vitro diagnostic test that is intended to predict fracture-risk in case of osteoporosis. The OsteomiR-Te...
2015-06-02 - 2015-12-31 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.